<ul>
<li><span><i>Midland WTI will be Underpinned by Magellan and Enterprise’s Combined Pipeline, Storage and Marine Export Facilities in the Houston Area</i></span></li>
</ul>
February 3, 2021 at 8:08 am Published by NCV Newswire
GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader
Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a potential near-term blockbuster
Enhanced product diversification of combined company expected to provide accelerated double-digit revenue growth
Anticipated to be accretive in first full year of combined operations and substantially accretive thereafter
Conference call today at 8:30 AM ET
DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or
Share this article
Share this article
DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.
Upon close of the transaction, the combined company will be a leader in neuroscience with a global commercial and operational footprint well positioned to maximize the value of its diversified portfolio.